India RNA Therapeutics Market Size Likely to Grow at a CAGR of 6.4% By 2035

The market in India is projected to reach around USD 50.5 million in 2025, USD 53.45 million in 2026 and USD 91.9 million in 2035 with a CAGR of 6.4% between 2026 and 2035.

India RNA Therapeutics Market Revenue and Trend

It is projected that the India RNA therapeutics market will follow a steady rise in revenue in 2026 to 2035 with increased usage of advanced RNA-based therapies like mRNA therapeutics, RNA interference (RNAi), antisense oligonucleotides, gene-silencing therapies, and emerging RNA platforms. Growing demand of these treatments is driven by the rising use of infectious diseases, cancer, genetic disease, metabolic and cardiovascular diseases and rare conditions. Increased investment in healthcare infrastructure in the public and privates, increased spending on healthcare, and the emphasis of precision medicine are boosting the access of patients with RNA therapeutics. Also, novel delivery systems, production technologies, and clinical development enhance efficacy, safety, and patient outcomes. The positive government policies, the rising clinical research activities as well as the enhancing distribution channels further contribute to the long-term market development.

Which Are the Factors Which Contribute Significantly?

The India RNA therapeutics marketplace is driven by the following key factors; the growing burden of chronic and genetic ailments, the growing awareness of healthcare, and the inclination to use advanced targeted treatment. RNA therapeutics are becoming more available and scalable through investments by pharmaceutical business organizations, both local and global, in research and development, clinical trials, and contract manufacturing organizations (CDMOs). In addition, the increasing partnerships with biotechnology companies, increased access to hospitals and specialized clinics, and increased insurance cover of advanced treatments are increasing adoption. Favourable regulatory environment, encouragement of biotech innovation and improved logistics and distribution networks are equally driving a stable market in the forecast period.

Segment Analysis

By Technology Type

The mRNA Therapeutics are found in the largest share of the RNA therapeutics market in India because of the proven efficacy of these mRNA Therapeutics with infectious diseases and cancer, and in preventive vaccines and therapeutic applications. RNA Interference (RNAi) is increasingly being used in treating genetic and rare diseases due to its performance in silencing certain genes. The use of Antisense Oligonucleotides (ASOs) is gaining popularity in metabolic and neurological diseases due to its specificity in the identification of RNA transcripts. The use of Gene-Silencing Therapy in oncology, and cardiovascular diseases is becoming a reality and is backed by clinical trials that show safety and efficacy. New RNA Platforms, including self-amplifying RNA and circular RNA, are being of interest as they present the possibility of rapid-production, reduced dose, and general-purpose therapeutic use. Other RNA technologies are also slowly penetrating the market as supportive therapy or combination therapy, which further increases the general market size of the RNA therapeutics in India.

By Therapeutic Application

The category of Infectious Diseases prevails because of the popularity of RNA vaccines and therapeutics against viral diseases, such as COVID-19, influenza, and dengue. Oncology (Cancer) is developing very fast due to the introduction of RNA-based therapies that offer solutions to hard-to-treat tumors. RNAi and ASOs are being adopted in Genetic Disorders, especially where there are few treatment options and the condition is a hereditary one. Metabolic Diseases, such as diabetes and obesity-related complications are RNA therapeutics targets because they have potential in gene regulation. RNA therapeutics targeting the inhibition or activation of gene expression correlated with heart disease and vascular diseases is being used to address Cardiovascular Diseases. Rare Diseases represent a major opportunity since RNA-based precision medicines are potential treatment opportunities whereby conventional therapies have failed. Other therapies like autoimmune diseases, neurological disorders are also being investigated and the RNA therapeutics in India are expanding.

By End User

The major end users of RNA therapeutics are hospitals due to their large volumes of patients, elaborate structures and the availability of special clinicians to handle complicated treatments. Genetic disorders, infectious disease, and oncology Specialty Clinics are broadening their RNA-based treatment and raising the adoption rates. Biotech Firms are also busy undertaking RNA research and development, funding clinical trials, and manufacturing investigational therapy. Pharmaceutical Companies are using RNA platforms in both local production and inter-country partnerships. Institutions of research are very important in preclinical trials, RNA delivery systems, and early stage innovation. As a growth in production, quality control, and commercialization, Contract Manufacturing Organizations (CDMOs) are becoming increasingly important. RNA therapeutics are gradually finding their way into the treatment regimens of other end users such as government health programs and diagnostic centers, especially in immunization programs and in rare disease programs.

Report Scope

Recent Developments

• Novartis India Ltd. has upgraded its research and development facility in India in December 2025 with improved technologies on RNA. The enhancement was oriented towards gene-silencing research to support the new therapies. This expansion will accelerate clinical testing in different treatment areas. It also increases the efficiency of commercialization of the company regarding RNA-based treatments. Overall, Novartis becomes a significant player in the Indian market of RNA therapeutics as a result of the relocation.

List of the prominent players in the India RNA Therapeutics Market:

• Biocon Limited

• Pfizer Inc.

• Gennova Biopharmaceuticals Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Bharat Biotech International Ltd.

• Zydus Lifesciences Limited

• Cipla Limited

• Sun Pharmaceutical Industries Ltd.

• Serum Institute of India Pvt Ltd

• Novartis India Ltd.

• Others

The India RNA Therapeutics Market is segmented as follows:

By Technology Type

• mRNA Therapeutics

• RNA Interference (RNAi)

• Antisense Oligonucleotides

• Gene-Silencing Therapies

• Emerging RNA Platforms

• Others

By Therapeutic Application

• Infectious Diseases

• Oncology (Cancer)

• Genetic Disorders

• Metabolic Diseases

• Cardiovascular Diseases

• Rare Diseases

• Others

By End User

• Hospitals

• Specialty Clinics

• Biotechnology Companies

• Pharmaceutical Companies

• Research Institutions

• Contract Manufacturing Organizations (CDMOs)

• Others